High-dose (9 MU) long-term (60 weeks) alfa-interferon therapy for chronic hepatitis patients infected with HCV genotype 1b

Archives of Virology

Volumn 143, Issue 8, 1998, Pages 1545-1554

  Kanai, K ^a   Kako, M ^b   Kumada, T ^c   Tsubouchi, H ^d   Aikawa, T ^e   Kojima, M ^f   Harada, H ^g   Kawasaki, T ^h   Nakashima, M ^h   Okamoto, H ⁱ   Mishiro, S ^a  

^a Shinagawa ku   (Japan)

^b TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c OGAKI MUNICIPAL HOSPITAL   (Japan)

^d UNIVERSITY OF MIYAZAKI   (Japan)

^e Aikawa Internal Hospital   (Japan)

^f Department of Medicine   (Japan)

^g National Hospital Organization   (Japan)

^h HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CHRONIC HEPATITIS; GENOTYPE; HEPATITIS C VIRUS; IMMUNOTHERAPY; VIRUS RNA;

GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A;

HEPATITIS C VIRUS;

EID: 7344259641     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007050050397     Document Type: Article

References (23)

1. Ballardini G, Groff P, Pontisso P, Giostra F, Francesconi R, Lenzi M, Zauli D, Alberti A, Bianchi FB (1995) Hepatitis C virus genotype, tissue HCV antigens, hepatocellular expression of HLA-A, B, C and intercellular adhesion-1 molecules. Clues to pathogenesis of hepatocellular damage and response to Interferon treatment in patients with chronic hepatitis C. J Clin Invest 95: 2067-2075
2. Ballardini G, Manzin A, Giostra F, Francesconi R, Groff P, Grassi A, Solforosi L, Ghetti S, Zauli D, Clementi M, Bianchi FB (1997) Quantitative liver parameters of HCV infection: relation to HCV genotypes, viremia and response to interferon treatment. J Hepatol 26: 779-786.
3. Chayama K, Arase Y, Tsubota A, Saito S, Ikeda K, Koida I, Kumada H (1992) Genotypical classification of hepatitis C virus genome with polymerase chain reaction using a mixed primer set. Acta Hepatol Jpn 33: 805-806
4. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, Van Thiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A, Hepatitis Interventional Therapy Group (1989) Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized, controlled trial. N Engl J Med 321: 1501-1506
5. Di Bisceglie AM, Hoofnagle JH, Krawczynski K (1993) Changes in hepatitis C virus antigen in liver with antiviral therapy. Gastroenterology 105: 858-862
6. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH (1989) Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 321: 1506-1510
7. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C (1996) Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1 b infection. N Engl J Med 334: 77-81
8. Gavier B, Martinez-Gonzalez MA, Riezu-Boj JI, Lasarte JJ, Garcia N, Civeira MP, Prieto J (1997) Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterology 113: 1647-1653
9. Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H, Kamada T (1993) Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 104: 877-883
10. Ichida F, Tsuji T, Omata M, IchidaT, Inoue K, Kaminuma T, Yamada G, Hino K (1996) New Inuyama classification; new criteria for histological assessment of chronic hepatitis. Int Hep Commun 6: 112-119
11. Kanai K, Kako M, Okamoto H (1992) HCV genotypes in chronic hepatitis C and response to interferon. Lancet 339: 1543
12. Kanai K, Kako M, Aikawa T, Kumada T, Kawasaki T, Hatahara T, Oka Y, Mizokami M, Sakai T, Iwata K, Okamoto H, Mayumi M, Mishiro S (1995) HCV RNA monitoring for tailored regimens of interferon therapy in hepatitis C. Biomed Pharmacother 49: 65-67
13. Lau JYN, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokami M, Neuwald PD, Wilber JC (1993) Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 341: 1501-1504
14. Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC, for the Australia Hepatitis C Study Group (1995) Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. J Hepatol 23: 487-496
15. Lindsay KL, Davis GL, Schiff ER, Bodenheimer HC, Balart LA, Dienstag JL, Perrillo RP, Tamburro CH, Goff JS, Everson GT, Silva M, Katkov WN, Goodman Z, Lau JYN, Maertens G, Gogate J, Sanghvi B, Albrecht J, Hepatitis Interventional Therapy Group (1996) Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatology 24: 1034-1040
16. Magrin S, Craxi A, Carmelo F, Simonetti RG, Fiorentino G, Marino L, Diquattro O, Di Marco V, Loiacono O, Volpe R, Almasio P, Urdea MS, Newald P, Sanchez-Pescador R, Detmer J, Wilbert J, Pagliaro L (1994) Hepatitis C viremia in chronic liver disease: relationship to interferon-alpha or corticosteroid treatment. Hepatology 19: 273-279
17. Okada S, Akahane Y, Suzuki H, Okamoto H, Mishiro S (1992) The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 16: 669-624
18. Okamoto H, Kobata S, Tokita H, Inoue T, Woodfield GD, Holland PV, Al-Knawy BA, Uzunalimoglu O, Miyakawa Y, Mayumi M (1996) A second-generation method of genotyping hepatitis C virus by the poly merase chain reaction with sense and antisense primers deduced from the core gene. J Virol Methods 57: 31-45
19. Okamoto H, Okada S, Sugiyama Y, Tanaka T, Sugai Y, Akahane Y, Machida A, Mishiro S, Yoshizawa H, Miyakawa Y, Mayumi M (1990) Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5′-noncoding region. Jpn J Exp Med 60: 215-222
20. Picciotto A, Callea F, Varagona G, Bardellini E, Borzone S, De Conca V, Vallarino E, Giudici-Cipriani A, Vitali A, Grasso A, Palombino MA, Dodero M, Marenco G, Menardo G, Celle G (1995) Lymphoblastoid interferon therapy in chronic hepatitis C: biochemical, virological and histological evaluation of two different doses. Liver 15: 20-24
21. Picciotto A, Brizzolara R, Campo N, Poggi G, Sinelli N, De Conca V, Giudici-Cipriani A, Grasso A, Marenco G, Menardo G, Dodero M, Celle G (1996) Two year interferon retreatment may induce a sustained response in relapsing patients with chronic hepatitis C [Abstract]. Hepatology 24: 273A
22. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, Payen JL, Sajus M, Costa JM, Vidaud M, Chaput JC, Multicenter Study Group (1995) A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 332: 1457-1462
23. Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, Higashi Y, Shibata M, Morishima T (1992) Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology 16: 293-299